{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:32:13Z","timestamp":1782739933837,"version":"3.54.5"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bertrand Accard and Patrick Gele from the Centre de Ressource Biologique of Lille University Hospital"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.lungcan.2020.05.008","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T02:32:54Z","timestamp":1590546774000},"page":"366-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma"],"prefix":"10.1016","volume":"146","author":[{"given":"Simon","family":"Baldacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Chiarle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Jamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wasielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Descarpentries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Copin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis B","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2020.05.008_bib0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/cancers10030062","article-title":"Tumor resistance against ALK targeted therapy-where it comes from and where it Goes","volume":"10","author":"Sharma","year":"2018","journal-title":"Cancers."},{"key":"10.1016\/j.lungcan.2020.05.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","author":"Mazi\u00e8res","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.05.008_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2020.05.008_bib0020","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung Cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"54","key":"10.1016\/j.lungcan.2020.05.008_bib0025","doi-asserted-by":"crossref","first-page":"92265","DOI":"10.18632\/oncotarget.21182","article-title":"Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer","volume":"8","author":"Awad","year":"2017","journal-title":"Oncotarget."},{"issue":"2","key":"10.1016\/j.lungcan.2020.05.008_bib0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2013","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.lungcan.2020.05.008_bib0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nm1769","article-title":"The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination","volume":"14","author":"Chiarle","year":"2008","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2020.05.008_bib0040","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/2326-6066.CIR-15-0089","article-title":"Efficacy of a Cancer vaccine against ALK-Rearranged lung tumors","volume":"3","author":"Voena","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"5151","key":"10.1016\/j.lungcan.2020.05.008_bib0045","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030427X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030427X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:56:57Z","timestamp":1759237017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022030427X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":9,"alternative-id":["S016950022030427X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}